COSMO BIO COMPANY,LIMITED (3386.T) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 5Aug 10Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

16.4x

EV/EBITDA

7.8x

Market Cap

JPY 7.11B

MomentumView details →

1D Return

−0.32%

YTD Return

−3.83%

RSI (14)

52.5

ValuationView details →

P/E (Fwd)

16.4x

EV/EBITDA

7.8x

Market Cap

JPY 7.11B

RSI (14)

52.5

MomentumView details →

1D Return

−0.32%

YTD Return

−3.83%

ProfitabilityView details →

Gross Margin

34.39%

Net Margin

3.13%

EBITDA Margin

4.74%

ROE (TTM)

3.39%

ROA (TTM)

2.66%

Asset Turnover

0.86x

GrowthView details →

Revenue YoY

+7.26%

EPS YoY

+31.67%

FCF YoY

—

Revenue CAGR 3Y

+4.07%

EPS CAGR 3Y

−12.72%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

5.23x

Quick Ratio

4.52x

Div Yield

2.00%

Div Rate

JPY 50.00

Div Growth 1Y

+0.00%

Financials snapshotView financials →

Revenue (TTM)

11.00B

Net Income (TTM)

347.00M

Op. CF (TTM)

—

Next earningsNov 11, 2026 →

Latest newsMore news →

Cosmo Bio signed an exclusive domestic distribution agreement with US-based Epigenome Technologies for epigenetics-related products and services.16d ago

Similar companies

KIMURA CO.,LTD.7461.T OTAKE CORPORATION7434.T Puequ CO.,LTD.9264.T TOMITA CO.LTD.8147.T KITAZAWA SANGYO CO.,LTD.9930.T Ascentech K.K.3565.T Find similar companies →

Latest newsMore news →

Cosmo Bio signed an exclusive domestic distribution agreement with US-based Epigenome Technologies for epigenetics-related products and services.16d ago